NCT01134705

Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol (320 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Adult and Adolescent Subjects (12 Years of Age and Older)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 474 (actual)
• Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of perennial allergic rhinitis.

Conditions

• Rhinitis, Allergic, Perennial

Interventions

Type	Name	Description
DRUG	Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol	Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
DRUG	Placebo Nasal Aerosol	HFA Vehicle Aerosol

Timeline

• Start date: 2010-05-01
• Primary completion: 2010-10-01
• Completion: 2010-10-01
• First posted: 2010-06-02
• Last updated: 2012-05-23
• Results posted: 2012-05-23

Locations

35 sites across 1 country: United States